A study analysing utility values associated with treatment attributes for Atypical Hemolytic Uremic Syndrome in 5 Countries
Latest Information Update: 20 Nov 2020
At a glance
- Drugs Ravulizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2020 New trial record
- 19 Nov 2020 Results presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research